Dr Alexandra Pender

Job title

Consultant medical oncologist



GMC Number


Contact details

PA/secretary phone number: 020 7794 0500 ext 32325 or 020 7830 2396

PA/secretary email address: Melanoma: Rf.melanomaoncologyteam@nhs.net Lung: p.masson@nhs.net

Related services

Cancer services


Dr Alexandra Pender is a consultant medical oncologist whose research interests include circulating tumour DNA in lung cancer, immunotherapy and clinical trials of new therapies in melanoma and lung cancer.  

She undertook translational and laboratory research at the Institute of Cancer Research from 2013-2016 leading to a PhD.  Her awards include the Innovative Protocol Award at the 2016 ESMO Workshop on methods in clinical cancer research and the Novartis Oncology Young Canadian Investigator Award.    


Effect of targeted therapy and immunotherapy on advanced non small-cell lung cancer outcomes in the real world Shokoohi A, Al-Hashami Z, Moore S, Pender A, Wong SK, Wang Y, Leung B, Wu J, Ho C. Cancer Med. 2022 Jan;11(1):86-93. doi: 10.1002/cam4.4427. Epub 2021 Nov 16. PMID: 34786889; PMCID: PMC8704182.

Imaging-Guided Palliative Procedures: Tendon and Bursa Injection. Chapter In: Interventional Radiology in Palliative Care Chavda A, Pender A, Cresswell M. (2021) Eds: Munk P.L., Babu S.B. Medical Radiology. Springer, Cham. https://doi.org/10.1007/978-3-030-65463-4_7.

Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors Pender A*, Titmuss E*, Pleasance E, Fan KY, Pearson H, Brown SD, Grisdale CJ, Topham JT, Yaoqing Shen Y, Bonakdar M, Taylor GA, Williamson LM, Mungall K, Chuah E, Mungall AJ, Moore RA, Lavoie J-M, Yip S, Lim H, Renouf DJ, Sun S, Holt RA, Jones SJM, Marra MA, and Laskin J Clin Cancer Res 2021 Jan ;27(1):202-212 *Joint first authors.

EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes Pender A, Hughesman C, Law E, Kristanti A, McNeil K, Wong S, Tucker T, Bosdet I, Young S, Laskin J, Karsan A, Yip S, Ho C Transl Lung Cancer Res 2020 Aug;9(4):1084-1092. doi: 10.21037/tlcr-19-581.PMID: 3295348.

Intratumoural Heterogeneity in PD-L1 Immunoreactivity is Associated with Variation in Non-Small Cell Lung Carcinoma Histotype Histopathology Naso JR, Wang G, Pender A, Wong SK, Zhu J, Ho C, Ionescu DN, Zhou C 2019 Aug 27. doi: 10.1111/his.13983

Lung Cancer in Canada Ho C, Lefresne S, Liberman M, McGuire A, Palma D, Pender A, Snow S, Tremblay A, Myers R, J Thorac Oncol 2019; 14 (7): 1128-33.

Optimising cancer vaccine design in sarcoma Pender A, Jones RL, Pollack S, Cancers 2018; 11 (1) pii: E1 doi: 10.3390/cancers11010001.

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma Pender A, Davis EJ, Chauhan D, Messiou C, Al-Muderis O, Thway K, Fisher C, Zaidi S, Miah A, Judson I, van der Graaf W, Keedy VL, Benson C, Jones RL, Med Oncol 2018 20;35(10):131 doi: 10.1007/s12032-018-1193-5.